1. Introduction {#sec1}
===============

Hematopoietic stem cell transplantation (HCT) is an intensive medical procedure used to treat a variety of hematologic malignancies and disorders whereby stem cells are infused into the recipient to replace a damaged immune system. This infusion follows complete or near-complete ablation of the recipient\'s immune system with chemotherapy and/or radiation. HCT involves significant emotional and immune challenges, with the highest level of psychosocial stress usually occurring during the early post-transplant phase (first 30 days) ([@bib31]). This period of time is also marked by significant immune suppression, high risk of infection, and other immunologic complications. The endocannabinoid (eCB) system is uniquely positioned to play a significant role in the peri-HCT period as it is a modulator of emotional reactivity and immune and inflammatory responses ([@bib18]). There are no reports of studies of the eCB system in the transplant setting.

Multiple psychosocial factors can affect outcomes after HCT ([@bib19]); in particular, pre-transplant depression and anxiety are associated with worse post-transplant survival ([@bib1], [@bib26]). Previous studies demonstrate that pre-transplant depression and anxiety are also associated with altered immune function during the post-transplant period ([@bib12], [@bib25], [@bib30], [@bib33], [@bib34]), with pro-inflammatory factors increasing in the immediate post-transplant period before gradually returning to baseline ([@bib41], [@bib42]). Further, pro-inflammatory pathways can mediate the relationship between psychosocial stress and poor outcomes ([@bib24], [@bib41], [@bib42]). These data suggest that the effects of pre-transplant psychosocial pathology negatively influence outcomes as a result of promoting a pro-inflammatory milieu.

The two most well-studied eCBs are 2-arachidonoylglycerol (2-AG) and *N*-arachidonylethanolamine or anandamide (AEA); both of these lipids are present in the circulation ([@bib18]). The immune system - specifically macrophages and platelets - is a significant source of eCB synthesis and release in response to endotoxins and cytokines ([@bib40]). In support of these data, previous studies demonstrate that circulating concentrations of 2-AG are increased during inflammation ([@bib2], [@bib6], [@bib8], [@bib43]). Other known sources include adipose tissue ([@bib29], [@bib39]) and reproductive organs ([@bib9]). Since the eCBs are lipophilic, it is likely that their concentrations in the circulation are also affected by overflow from tissues with high eCB contents, including the brain ([@bib3]).

Previous studies of circulating eCB concentrations have demonstrated significant correlations with both depression and inflammation. Concentrations of 2-AG are significantly lower in individuals diagnosed with major depression ([@bib13], [@bib16]). Other studies demonstrate that circulating concentrations of 2-AG are increased during pro-inflammatory states ([@bib2], [@bib6], [@bib8]) and are positively correlated with concentrations of interleukin 6 (IL-6) ([@bib43]). These data led us to hypothesize that the profound suppression of the immune system that occurs during the process of HCT results in loss of eCBs in the circulation. We further hypothesized that depression in this population would be associated with lower circulating 2-AG concentrations as has been seen in other populations.

In this pilot study, we were able to test these specific hypotheses: 1) concentrations of the eCBs are altered over time in HCT recipients; and 2) circulating concentrations of the eCBs are positively correlated with pro-inflammatory molecules and negatively correlated with depression in the peri-transplant period. We further explored the association between the eCBs and anxiety as well as changes in inflammatory markers, depression, and anxiety over time.

2. Methods {#sec2}
==========

2.1. Patients {#sec2.1}
-------------

A total of 19 men and women who underwent HCT at the University of Rochester Medical Center (URMC) between May 2010 and May 2011 for any reason participated in this study. To be eligible for the study, participants had to be at least 18 years of age, English speaking, and able to complete self-report inventories. Exclusion criteria included conditions preventing meaningful participation in the research interview, for example, major, uncorrected sensory impairments, severe communication limitations such as aphasia, active psychosis, or acute substance intoxication at the time of the initial interview as assessed by the study PI (JMK). Participants were recruited through the study PI after being identified by their transplant physician at their pre-transplant visit in the URMC outpatient HCT clinic. Written informed consent was obtained prior to study participation.

2.2. Procedures {#sec2.2}
---------------

First, participants completed a packet of demographic information in addition to the clinical surveys. At the same time, a 30 ml blood sample was drawn by venipuncture of the antecubital vein or from central venous access, if available, by a trained nurse or phlebotomist (time point 1, T1). T1 ranged from 1 to 18 days prior to transplant (median = 7.5), and always preceded pre-conditioning regimens. Surveys were administered and blood collected at two additional time points: at the time of hospital discharge following initial transplant admission (T2) and as close to day 100 following transplant as possible (T3). T2 collection time ranged from day 9 to day 17 post-transplant (median = 12.5) and T3 ranged from day 91 to day 175 post-transplant (median = 104). Blood specimens were obtained between 0900 h and 1400 h and were centrifuged for 10 min at 1000 × g. The plasma was then aspirated, divided into aliquots, and stored at −80 °C. Plasma analyses were performed at the Medical College of Wisconsin (MCW). Both the URMC and MCW Institutional Review Boards approved these procedures.

2.3. Plasma endocannabinoid extraction and measurement {#sec2.3}
------------------------------------------------------

Concentrations of AEA and 2-AG were determined simultaneously in the same plasma sample. Plasma samples (0.5 ml each) were thawed and made up to 15% ethanol, to which the internal standards \[^2^H~8~\]-AEA (16.9 pmol) and \[^2^H~8~\]-2-AG (46.5 pmol) (Cayman Chemicals, Ann Arbor, MI) were added. Samples were vortexed and centrifuged at 1000 × g for 4 min. The supernatant was loaded onto Bond Elut C18 solid-phase extraction columns (1 ml; Varian Inc, Lake Forest, CA) which had been conditioned with 1 ml redistilled ethanol and 3 ml of double distilled water (ddH2O). The remaining pellet was washed with 100 μl of 15% ethanol and centrifuged again for 3 min. The resulting supernatant was also loaded onto the C18 column. Columns were washed with 5 ml ddH~2~O and eluted with 1 ml of ethyl acetate. The ethyl acetate layer in the resulting eluate was removed and dried under N~2~. Lipids in the residual ddH~2~O phase were extracted by mixing with an additional 1 ml of ethyl acetate, which was added to the original ethyl acetate solution. Once dried, samples were resuspended in 20 μl of methanol and stored at −80 °C. AEA and 2-AG were quantified using liquid chromatography-atmospheric pressure chemical ionization-mass spectrometry (LC-APCI-MS); selective ion monitoring was used to quantify the biogenic lipids as described previously ([@bib15]).

2.4. Quantitative determination of cytokines in human plasma {#sec2.4}
------------------------------------------------------------

Cytokines were quantified in human plasma using Fluorokine MAP multiplex kits (R&D Systems, Inc., Minneapolis, MN) according to the manufacturer\'s protocol. The Human High Sensitivity Cytokine Base Kit was used with corresponding Fluorokine MAP analyte-specific bead sets to detect interleukin (IL)-1β, IL-6, IL-8, IL-10, IL-12p70, interferon (IFN)-γ, tumor necrosis factor (TNF)-α, and vascular endothelial growth factor (VEGF) protein concentrations in plasma samples diluted 2-fold. C-reactive protein (CRP) was detected using the Human Cardiac Base Kit B with Fluorokine MAP analyte-specific bead sets for CRP in plasma samples diluted 1000-fold. Detection and quantitative analysis of each analyte was performed on the Luminex 200 system with integrated software (v2.3) capable of generating a five parameter logistic curve-fit. Median Fluorescent Intensity (MFI) was collected by assigning the bead region for each analyte being measured at the following instrument settings: Sample Timeout of 100 s, Minimum beads = 50, Sample size of 50ul, and Doublet Discriminator gates set at 7500 and 15,500.

2.5. Psychosocial factors {#sec2.5}
-------------------------

The **Demographic Questionnaire** is a 12-item self-report questionnaire that contains items concerning demographics, socioeconomic status, and living circumstances.

**Center for Epidemiologic Studies Depression Scale -- Revised (CES-D-R)** ([@bib10]): A 20-item self-report questionnaire mapping items that form the diagnostic criteria for major depression; scores range from zero to 60, while a threshold score of 16 may be a sign of significant depression.

**State-Trait Anxiety Inventory (STAI)** ([@bib38]): a 40-item self-report inventory that is widely used and thoroughly validated to measure anxiety in adults; we assessed the more general and long-standing "trait anxiety" (STAI-T) using 20 questions.

2.6. Statistics {#sec2.6}
---------------

The cytokine and endocannabinoid measurements were found to have a wide dynamic range and highly skewed distribution. Since these findings complicated and/or invalidated planned analyses, the biomarker measurements were transformed using a base-10 logarithmic transformation. Values below the lower limit of the detection of the biomarkers were replaced by the lower limit of detection; this is a conservative approach that is unlikely to lead to overestimation of differences. Biomarkers with over 25% of values below the limit of detection (IL-1β, IFN-γ, IL-12p70) were excluded from the analysis. The psychological questionnaire scores were not transformed.

Descriptive statistics (mean ± SD, median and range) were calculated separately for each of the three time points. The effect of time was tested separately for each variable by using a generalized estimating equations (GEE) model with an exchangeable working correlation structure to account for the repeated measurements within each subject. An ANOVA-like hypothesis of no change over time versus any patterns of change was tested. Within each time-point, Pearson\'s correlation analysis was also used to examine the cross-sectional relationship between the eCBs and the psychosocial factors and inflammatory molecules.

3. Results {#sec3}
==========

Demographic data for study participants are presented in [Table 1](#tbl1){ref-type="table"}. Nineteen subjects were enrolled, with 17 providing baseline demographic data. Subjects had a mean age of 55 (SD 12.5), were entirely Caucasian (100%), and the majority were married (76%). Less than half of the participants were employed full time (47%). Their diagnoses included acute myelogenous leukemia (5), lymphoma (4), and multiple myeloma (10). Fourteen patients received autologous, and 5 received allogeneic (4 sibling, 1 matched unrelated donor) transplants; all received peripheral blood stem cells and all but two patients received inpatient transplants.

3.1. Changes over time of biomarkers and psychosocial factors {#sec3.1}
-------------------------------------------------------------

The means and standard deviations of the biomarkers and psychosocial measurements at each time point T1-T3 (before transplant, at the time of hospital discharge, and 100 days following transplant) are reported in [Table 2](#tbl2){ref-type="table"}, which also illustrates the direction of change over time for each variable. Among the biomarkers evaluated, TNF-α, IL-6, IL-10, CRP, and VEGF significantly varied among the three time points, with T2 being a significant inflection point for most inflammatory molecules. The pattern of change for these significant variables, except VEGF and TNF-α, was to increase from T1 to T2 and decrease again at T3; VEGF was significantly decreased at T2 compared to T1 or T3 and TNF-α did not decline at T3. Circulating eCB concentrations were not significantly different among these three time points.

Depressive symptoms (CES-D) and anxiety (STAI-T) changed significantly over time ([Table 2](#tbl2){ref-type="table"}). Anxiety was highest preceding transplant (T1) while depressive symptoms (CES-D) peaked at hospital discharge (T2). Four participants (26.7%) reported significant depressive symptoms (CES-D ≥ 16; ([@bib5])) at T1; 50% reported such symptoms at T2 and 0% at T3. There was greatest study attrition at T3; this appeared to be a more prevalent pattern among those endorsing significant depressive symptoms at T2. Clinically meaningful cut-points for the STAI-T have not been adequately demarcated in the literature.

3.2. The eCBs and their correlation with psychosocial factors and inflammatory molecules {#sec3.2}
----------------------------------------------------------------------------------------

Correlations between the eCBs and the pro-inflammatory mediators were examined individually at the three time points. Pearson correlation analyses demonstrated a significant positive association between 2-AG concentrations and IL-6 and CRP at T1 (IL-6, r = 0.54, p = 0.02; CRP, r = 0.64, p \< 0.01) and T3 (IL-6, r = 0.64, p = 0.01; CRP, r = 0.59, p = 0.03), but not at T2 ([Fig. 1](#fig1){ref-type="fig"}). The correlations between psychosocial factors and the eCBs demonstrate a significant association between greater depressive symptoms and lower 2-AG levels at T1 (r = −0.64, p = 0.01; data not shown). There were no significant associations between 2-AG and depressive symptoms at T2 or T3. There was no significant relationship between anxiety and the eCBs at any of the time points.

4. Discussion {#sec4}
=============

In the present HCT sample, 2-AG and IL-6 concentrations are significantly, positively correlated in the peri-HCT setting. IL-6 and 2-AG concentrations are significantly correlated at T1, prior to transplantation, and T3, approximately 100 days post transplant. This correlation is consistent with that seen in individuals undergoing cardiopulmonary bypass, another markedly pro-inflammatory medical condition ([@bib43]). 2-AG is also significantly positively associated with the pro-inflammatory marker CRP in samples taken at T1 and T3, a relationship not previously reported in the literature. The strength of the correlations between 2-AG and both IL-6 and CRP are remarkably similar at T1 and T3. However, there was no correlation between 2-AG and either IL-6 or CRP at T2, when the concentrations of the cytokines were the highest of the time points sampled. We hypothesize that the loss of correlation at this time point reflects a change in the source of either the cytokines or 2-AG, resulting in an uncoupling of this relationship. Consistent with prior literature ([@bib13]), 2-AG demonstrates an inverse relationship with depressive symptoms in the present HCT sample but only at T1.

As demonstrated in prior studies with HCT patients ([@bib41], [@bib42]), pro-inflammatory molecules are elevated at T2 in the present sample despite a decrease in bone marrow-derived hematopoiesis and general immune cell production. Indeed, cytokines are produced by many different types of cells; Kupffer cells, the resident tissue macrophages of the liver, are able to synthesize a variety of cytokines ([@bib35]) and perivascular fat locally produces pro-inflammatory cytokines ([@bib20]). Pre-transplant chemotherapy regimens may evoke this large cytokine response. Interestingly, however, the circulating concentration of 2-AG was unchanged at T2 compared to T1 and T3. This is in contrast to our hypothesis, which predicted that 2-AG concentrations would be reduced when the bone marrow-derived cell numbers are suppressed. This suggests that the mechanisms regulating circulating concentrations of 2-AG are complex and include non-inflammatory processes. In addition, the present findings suggest that the immune system may not be the primary source of circulating eCBs in the context of HCT, as their levels remain consistent despite significant immune suppression.

As previously identified in non-transplant populations ([@bib16], [@bib18]), circulating 2-AG concentrations are negatively correlated with depressive symptoms in this study of HCT recipients. The relationship between 2-AG and depression is present only at T1. Preclinical data support the hypothesis that 2-AG reduces depressive symptoms as a result of activation of brain CB1 receptors (CB1R) ([@bib17]). Since 2-AG concentrations did not fall during T2, it is possible that CB1R in the brain have lost responsivity to 2-AG during this period. This hypothesis is supported by the down regulation of CB1R in animals exposed to chronic unpredictable stress ([@bib14]), as would be similar to the clinical scenario of a stem cell transplant. Alternatively, the data could suggest that a relatively intact immune system is necessary for this relationship between depressive symptoms and 2-AG to occur, as evidenced by the absence of this relationship at assessment time points following transplantation when the host\'s immune system is compromised. In sum, additional work is required to ascertain whether peripheral or central changes - or both - contribute to this change in relationship between 2-AG and depression just after transplant.

At T1 and T3, our data demonstrate a significant and positive association between the concentrations of IL-6 and 2-AG. Several recent studies provide evidence to support the hypothesis that 2-AG potentiates IL-6 production and suggest that 2-AG could be up-stream of IL-6. For example, 2-AG containing sera increases LPS-induced IL-6 expression in a macrophage cell line ([@bib27]). Inhibition of 2-AG catabolism fully blocked diclofenac-induced increases in gastric concentrations of IL-6, an effect that required the CB1 receptor ([@bib23]). Activation of CB1R in human adipocyte cultures produces a delayed increase in IL-6 protein release ([@bib11]). Finally, CB2 receptor deficiency results in reduced IL-6 production and mortality in polymicrobial sepsis ([@bib7]).

2-AG and its primary receptors, CB1 and CB2, exert complex effects on the immune system. Both anti-inflammatory and pro-inflammatory effects have been reported, depending upon the cell type and the state of underlying inflammation. For example, loss of CB2 receptors on T cells results in higher T cell entry into the brain and greater cytokine concentrations in a mouse model of multiple sclerosis ([@bib28]). Inhibition of 2-AG catabolism reduces LPS-induced increases in brain cytokine production; an effect that is attenuated by CB1 receptor blockade ([@bib22]). On the other hand, CB2 receptor deficiency leads to reduced neuroinflammation in a mouse model of Alzheimer\'s Disease ([@bib36]). As described above, data that 2-AG can increase release of IL-6 are consistent with the findings of this study. However, the results of this study are purely correlative and do not shed light on potential causative relationships between 2-AG and IL-6 or CRP.

It is noteworthy that during the time of greatest psychosocial distress (immediately following transplant) and immune suppression, the relationships among the eCB system and emotion response and immune function becomes uncoupled. Given the preclinical data of stress buffering effects of the eCBs ([@bib17]), it is possible that the dysregulated neuroimmune-2-AG relationship renders HCT recipients more vulnerable to psychosomatically mediated disease processes during the immediate peri-HCT time period. The potential for the eCB system to buffer against psychosocially mediated inflammation is important given the contribution of inflammation to adverse medical outcomes among HCT recipients, including early mortality, graft-versus-host disease, graft rejection, infection, and disease relapse ([@bib4], [@bib21], [@bib24], [@bib32], [@bib37]).

This dysregulation may also contribute to the previously observed increased rates of psychopathology among HCT recipients in the immediate post-transplant time period due to a lack of eCB buffering of emotional reactivity. Since the eCB effect on depression was lost without a reduction in 2-AG at T2, this suggests that the CB1R in the brain may have lost responsivity during this period. The present findings provide a basis for further evaluation in rodent models to clarify the specific neuroimmune and behavioral implications of our preliminary findings. It is worthwhile to continue investigation of the interplay of these pathways as the eCB system may hold promise as a possible therapeutic target in this and other medically vulnerable populations.

The major limitations of the present study are the small and heterogeneous sample, thus these data are exploratory. Due to the sample size limitation, we were unable to control for possibly confounding medical and demographic variables. Despite these limitations, the present results are consistent with previous research involving patterns of change in psychosocial and inflammatory molecules, suggesting that the present data on circulating eCBs -- a biomarker not previously investigated in the HCT setting -- may indeed be generalizable to other HCT populations. Future studies with HCT patients investigating the eCB system should aim to recruit larger samples of more homogeneous diseases to control for possible patient and disease confounders such as preparative regimens, transplant type, disease and disease status, and other contributors to inflammatory status including body mass index (BMI), medications, and smoking. Despite its inherent limitations, the current data provide information suggestive for future study regarding the role of the eCB signaling system in the peri-HCT period.

5. Conclusions {#sec5}
==============

2-AG is significantly, positively associated with both IL-6 and CRP in HCT recipients. However, this relationship is lost immediately post-transplant at the time of greatest immunosuppression. The fact that these correlations are not consistent suggests that multiple mechanisms regulate circulating 2-AG concentrations. 2-AG is negatively correlated with depressive symptoms in HCT recipients, as has been demonstrated in other populations. Further work is needed to understand the etiology and regulatory pathways involved in eCB signaling in the immediate post-transplant period to elucidate potential roles for risk prognostication, stress buffering, and therapeutic targets.
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###### 

Demographic characteristics of sample population.

                                          N = 17
  --------------------------------------- ----------------
  Mean Age                                55 (SD 12.5)
  **Gender**                              
  Male                                    9 (53%)
  Female                                  8 (47%)
  **Race/Ethnicity**                      
  Caucasian                               17 (100%)
  **Marital Status**                      
  Married                                 13 (76%)
  Divorced                                3 (18%)
  Single                                  1 (6%)
  **Living Arrangements**                 
  Spouse/significant other                9 (53%)
  Spouse/significant other and children   4 (23.5%)
  Other                                   4 (23.5%)
  Education (mean years)                  14.47 (2.0 SD)
  **Employment status**                   
  Full time                               8 (47%)
  Retired                                 3 (18%)
  Disability                              4 (23%)
  Other                                   2 (12%)
  **Income**                              
  \$10,000--\$49,999                      4 (24%)
  \$50,000--\$99,999                      7 (41%)
  ≥\$100,000                              3 (17.5%)
  Don\'t know/No response                 3 (17.5%)

###### 

Summary statistics for biomarkers and psychosocial factors across time points. A GEE model was used separately for each variable to test for the effect of time.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Biomarkers              Time 1[a](#tbl2fna){ref-type="table-fn"} N = 18\   Time 2[a](#tbl2fna){ref-type="table-fn"} N = 14\   Time 3[a](#tbl2fna){ref-type="table-fn"} N = 14\   p-value[b](#tbl2fnb){ref-type="table-fn"}
                          Mean (SD)\                                         Mean (SD)\                                         Mean (SD)\                                         
                          Median (min--max)                                  Median (min--max)                                  Median (min--max)                                  
  ----------------------- -------------------------------------------------- -------------------------------------------------- -------------------------------------------------- -------------------------------------------
  TNF-α (pg/mL)           9.0 (2.3)\                                         13.9 (6.3)\                                        13.9 (13.0)\                                       \<0.01
                          8.8 (5.2--13.6)                                    10.0 (7.6--23.0)                                   9.1 (4.6--57.0)                                    

  IL-6 (pg/mL)            3.7 (3.9)\                                         9.5 (7.3)\                                         4.0 (4.5)\                                         \<0.0001
                          2.1 (1.0--14.8)                                    8.5 (1.9--28.9)                                    2.8 (1.0--18.2)                                    

  IL-8 (pg/mL)            24.6 (35.1)\                                       14.7 (14.5)\                                       19.3 (16.9)\                                       0.15
                          11.9 (5.4--134.4)                                  9.1 (3.8--51.4)                                    13.3 (2.6--62.6)                                   

  IL-10 (pg/mL)           1.5 (1.7)\                                         11.3 (13.9)\                                       1.3 (0.9)\                                         \<0.0001
                          1.0 (0.5--7.4)                                     2.4 (0.5--33.8)                                    1.2 (0.5--4.0)                                     

  CRP (μg/mL)             11.5 (11.7)\                                       66.7 (38.7)\                                       9.1 (9.9)\                                         \<0.001
                          8.1 (0.1--38.1)                                    62.7 (6.5--105.0)                                  4.3 (0.2--33.1)                                    

  VEGF (pg/mL)            64.3 (31.5)\                                       51.4 (31.3)\                                       89.8 (61.5)\                                       \<0.0001
                          61.9 (15.7--141.4)                                 43.3 (12.5--106.6)                                 70.4 (23.9--272.0)                                 

  2-AG (pmol/mL)          152.5 (208.1)\                                     146.6 (169.0)\                                     116.1 (156.1)\                                     0.69
                          98.4 (17.8--848.2)                                 60.9 (32.1--549.6)                                 59.1 (17.6--604.4)                                 

  AEA (pmol/mL)           1.7 (1.0)\                                         1.4 (0.5)\                                         1.2 (0.6)\                                         0.18
                          1.3 (0.8--5.0)                                     1.5 (0.5--2.3)                                     0.9 (0.6--3.1)                                     

  Psychosocial factors\   N = 15                                             N = 10                                             N = 9                                              
  Mean (SD)                                                                                                                                                                        

  CES-D                   9.3 (9.4)\                                         17.8 (13.6)\                                       5.6 (5.1)\                                         \<0.01
                          6 (1--27)                                          15 (3--42)                                         5 (0--15)                                          

  STAI-T                  39.0 (12.1)\                                       33.8 (11.4)\                                       31.9 (8.7)\                                        0.01
                          35 (25--61)                                        32.5 (22--60)                                      29 (20--47)                                        
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Time 1 = Before transplant (Day −1 -- Day −8); Time 2 = Time of hospital discharge (Day +9 -- Day +17); Time 3 = 100 days post-transplant (Day +91 -- Day +175).

GEE-based test for equal mean at all time-points.

[^1]: Study recruitment completed while author was part of the Rochester Center for Mind-Body Research in the Department of Psychiatry, University of Rochester Medical Center.

[^2]: Co-senior authors.
